Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLP-1002 First-in-human Study
NCT03760913Phase 1Completed
- Sponsor
- OliPass Corporation
- Start
- Nov 2018
- Primary completion
- Oct 2020
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OLP-1002 in pain (4 arms), sponsored by OliPass Corporation. Primary endpoints: Number of Participants With Adverse Events Stratified by Overall and Severity, Number of Participants Who Experienced Clinically Important Changes in Supine Diastolic and Systolic Blood Pressure and 7 more. Started Nov 2018; status: completed.
02
Drugs
OLP-1002
03
Conditions
pain
Beyond the preview
Go deeper on NCT03760913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760913.